Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trilaciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 16/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 3/20 | 0.98 |
| ▸ | CDK2 | P24941 | 20/20 | 0.98 |
| ▸ | CCND1 | P24385 | 16/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.98 |
| ▸ | CCND3 | P30281 | 3/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.98 |
| ▸ | CDK9 | P50750 | 2/20 | 0.98 |
| ▸ | TTK | P33981 | 1/20 | 0.82 |
| ▸ | FLT3 | P36888 | 1/20 | 0.82 |
| ▸ | CCNH | P51946 | 1/20 | 0.82 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.82 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.82 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trilaciclib SCHEMBL29375833 | 1.00 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL10082028 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29763763 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29356370 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL4549924 | 0.98 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551643 | 0.92 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL10082029 | 0.92 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Lerociclib SCHEMBL23711495 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Lerociclib SCHEMBL29409994 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Lerociclib SCHEMBL29409995 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136610-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-05-01 | — | — | US | claimed |
| EP-4486458-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | Teva Pharmaceuticals International GmbH (CH) | 2025-01-08 | — | — | EP | claimed |
| WO-2023164255-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-08-31 | — | — | WO | claimed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| US-12497404-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2025-12-16 | — | — | US | disclosed |
| EP-4225758-B1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | ASSIA CHEM IND LTD (IL) | 2025-11-26 | — | — | EP | disclosed |
| US-12479855-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2025-11-25 | — | — | US | disclosed |
| EP-4626866-A1 | NOVEL TRILACICLIB INTERMEDIATES, METHOD OF PREPARATION AND USE THEREOF | Assia Chemical Industries Ltd. (IL) | 2025-10-08 | — | — | EP | disclosed |
| US-20250243213-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-31 | — | — | US | disclosed |
| US-20250243214-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-31 | — | — | US | disclosed |
| US-20250243212-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | PHARMACOSMOS HOLDING A/S (DK) | 2025-07-31 | — | — | US | disclosed |
| EP-4486458-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | Teva Pharmaceuticals International GmbH (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-12168666-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | G1 THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240217984-A1 | PREPARATION METHOD OF TRILACICLIB AND PRECURSORS OF TRILACICLIB | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2024-07-04 | — | — | US | disclosed |
| US-12006324-B1 | Preparation method of trilaciclib and precursors of trilaciclib | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2024-06-11 | — | — | US | disclosed |
| WO-2024116069-A1 | NOVEL TRILACICLIB INTERMEDIATES, METHOD OF PREPARATION AND USE THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2024-06-06 | — | — | WO | disclosed |
| US-20230374028-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2023164255-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-08-31 | — | — | WO | disclosed |
| EP-4164653-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | G1 Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2022076779-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136610-A1 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | ALK, BRAF, FLT3 | CDK4 85/4885CDK6 269/4885CDK2 166/4885 |
| US-12006324-B1 | Preparation method of trilaciclib and precursors of trilaciclib | BRAF, ABL1, MCL1 | CDK4 15/4885CDK6 17/4885CDK2 14/4885 |
| US-20250243213-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | MCL1, ETV6, ALK | CDK4 20/4885CDK6 37/4885CDK2 50/4885 |
| US-20230374028-A1 | SOLID STATE FORMS OF TRILACICLIB AND OF TRILACICLIB SALTS | BRAF, FLT3, KRAS | CDK4 8/4885CDK6 35/4885CDK2 15/4885 |
| US-12479855-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | MCL1, ETV6, ALK | CDK4 20/4885CDK6 37/4885CDK2 50/4885 |
| US-20250243214-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | MCL1, ETV6, ALK | CDK4 20/4885CDK6 37/4885CDK2 50/4885 |
| US-20240217984-A1 | PREPARATION METHOD OF TRILACICLIB AND PRECURSORS OF TRILACICLIB | BRAF, ABL1, MCL1 | CDK4 15/4885CDK6 17/4885CDK2 14/4885 |
| US-20250243212-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | MCL1, ETV6, ALK | CDK4 20/4885CDK6 37/4885CDK2 50/4885 |
| US-12497404-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | MCL1, ETV6, ALK | CDK4 20/4885CDK6 37/4885CDK2 50/4885 |
| US-12168666-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | MCL1, ALK, ABL1 | CDK4 34/4885CDK6 51/4885CDK2 125/4885 |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | CTNND1, FLT3, MEF2D | CDK4 129/4885CDK6 296/4885CDK2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.